Enanta Pharma (ENTA) Misses Q4 EPS by 2c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.27), $0.02 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $20.32 million versus the consensus estimate of $22.87 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Nike names former Pfizer CFO David Denton as new finance chief